C-JUN prevents methylation of p16INK4a (and Cdk6): The villain turned bodyguard

Oncotarget

Volumn 2, Issue 5, 2011, Pages 422-427

  Kollmann, Karoline ^a   Heller, Gerwin ^b   Sexl, Veronika ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AP 1; CDK6; Leukemia; P16

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; MESSENGER RNA; PROTEIN C JUN; PROTEIN P53; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB; MUTANT PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CYCLIN DEPENDENT KINASE 6 GENE; DNA METHYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE EXPRESSION REGULATION; GENE INACTIVATION; HUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; TUMOR SUPPRESSOR GENE; ANIMAL; CELL TRANSFORMATION; DISEASE COURSE; DISEASE MODEL; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; LEUKEMIA; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PROMOTER REGION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA; MICE; MUTANT PROTEINS; PROMOTER REGIONS, GENETIC;

EID: 80053424501     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.279     Document Type: Article

References (57)

1. Kollmann K, Heller G, Ott RG, Scheicher R, Zebedin-Brandl E, Schneckenleithner C, Simma O, Warsch W, Eckelhart E, Hoelbl A, Bilban M, Zochbauer-Muller S, Malumbres M, Sexl V. c-JUN promotes BCR-ABLinduced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. Blood. 2011; 117:4065-4075.
2. Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene. 2001; 20:2413-2423.
3. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991; 1072:129-157.
4. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003; 3:859-868.
5. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene. 2001; 20:2401-2412.
6. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene. 2001; 20:2438-2452.
7. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A. 1991; 88:3720-3724.
8. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 1997; 9:240-246.
9. Schorpp-Kistner M, Wang ZQ, Angel P, Wagner EF. JunB is essential for mammalian placentation. EMBO J. 1999; 18:934-948.
10. Eferl R, Sibilia M, Hilberg F, Fuchsbichler A, Kufferath I, Guertl B, Zenz R, Wagner EF, Zatloukal K. Functions of c-Jun in liver and heart development. J Cell Biol. 1999; 145:1049-1061.
11. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M. Phorbol ester-inducible genes contain a common cis element recognized by a TPAmodulated trans-acting factor. Cell. 1987; 49:729-739.
12. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell. 1988; 55:917-924.
13. Turner R, Tjian R. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFoscJun heterodimers. Science. 1989; 243:1689-1694.
14. Lee W, Mitchell P, Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell. 1987; 49:741-752.
15. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002; 4:E131-136.
16. Suzuki T, Hashimoto Y, Okuno H, Sato H, Nishina H, Iba H. High-level expression of human c-jun gene causes cellular transformation of chicken embryo fibroblasts. Jpn J Cancer Res. 1991; 82:58-64.
17. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 1995; 92:11746-11750.
18. Bos TJ, Bohmann D, Tsuchie H, Tjian R, Vogt PK. v-jun encodes a nuclear protein with enhancer binding properties of AP-1. Cell. 1988; 52:705-712.
19. Maki Y, Bos TJ, Davis C, Starbuck M, Vogt PK. Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci U S A. 1987; 84:2848-2852.
20. Johnson R, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol. 1996; 16:4504-4511.
21. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature. 1991; 354:494-496.
22. Yang MY, Liu TC, Chang JG, Lin PM, Lin SF. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood. 2003; 101:3205-3211.
23. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001; 20:2390-2400.
24. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell. 2004; 119:431-443.
25. Szabowski A, Maas-Szabowski N, Andrecht S, Kolbus A, Schorpp-Kistner M, Fusenig NE, Angel P. c-Jun and JunB antagonistically control cytokine-regulated mesenchymalepidermal interaction in skin. Cell. 2000; 103:745-755.
26. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 1999; 21:326-329.
27. Passegue E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J. 2000; 19:2969-2979.
28. Szremska AP, Kenner L, Weisz E, Ott RG, Passegue E, Artwohl M, Freissmuth M, Stoxreiter R, Theussl HC, Parzer SB, Moriggl R, Wagner EF, Sexl V. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood. 2003; 102:4159-4165.
29. Andrecht S, Kolbus A, Hartenstein B, Angel P, Schorpp-Kistner M. Cell cycle promoting activity of JunB through cyclin A activation. J Biol Chem. 2002; 277:35961-35968.
30. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000; 19:2056-2068.
31. Chiu R, Angel P, Karin M. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell. 1989; 59:979-986.
32. Young MR, Farrell L, Lambert P, Awasthi P, Colburn NH. Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun. Mol Carcinog. 2002; 34:72-77.
33. Dhar A, Hu J, Reeves R, Resar LM, Colburn NH. Dominantnegative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene. 2004; 23:4466-4476.
34. Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT. Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. Mol Cancer Res. 2003; 1:848-854.
35. Thompson EJ, MacGowan J, Young MR, Colburn N, Bowden GT. A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. Cancer Res. 2002; 62:3044-3047.
36. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, Wagner EF. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003; 112:181-192.
37. Young MR, Li JJ, Rincon M, Flavell RA, Sathyanarayana BK, Hunziker R, Colburn N. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A. 1999; 96:9827-9832.
38. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P, Wagner EF. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999; 13:607-619.
39. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999; 18:188-197.
40. Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell. 2000; 103:897-907.
41. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, Doi S, Santella RM, Weinstein IB. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 1993; 8:3447-3457.
42. Maeno K, Masuda A, Yanagisawa K, Konishi H, Osada H, Saito T, Ueda R, Takahashi T. Altered regulation of c-jun and its involvement in anchorage-independent growth of human lung cancers. Oncogene. 2006; 25:271-277.
43. Liu JH, Yen CC, Lin YC, Gau JP, Yang MH, Chao TC, Hsiao LT, Wang WS, Tsai YC, Chen PM. Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia. Leuk Lymphoma. 2004; 45:2419-2425.
44. Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol. 2006; 37:668-674.
45. Arykok AT, Onal BU, Han U. Expressions of cyclin D1, p53, bcl-2, and bax in infiltrative ductal carcinoma of the breast: correlations with clinicopathologic characteristics. Breast J. 2006; 12:391-392.
46. Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M, Heller G, Zochbauer S, Wagner EF, Freissmuth M, Sexl V. JunB is a gatekeeper for B-lymphoid leukemia. Oncogene. 2007; 26:4863-4871.
47. Sherr CJ. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians. 1995; 107:181-186.
48. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005; 30:630-641.
49. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer. 1999; 35:1886-1894.
50. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, Dubus P, Barbacid M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004; 118:493-504.
51. Matushansky I, Radparvar F, Skoultchi AI. CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene. 2003; 22:4143-4149.
52. Ericson KK, Krull D, Slomiany P, Grossel MJ. Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes. Mol Cancer Res. 2003; 1:654-664.
53. Ogasawara T, Kawaguchi H, Jinno S, Hoshi K, Itaka K, Takato T, Nakamura K, Okayama H. Bone morphogenetic protein 2-induced osteoblast differentiation requires Smadmediated down-regulation of Cdk6. Mol Cell Biol. 2004; 24:6560-6568.
54. Ogasawara T, Katagiri M, Yamamoto A, Hoshi K, Takato T, Nakamura K, Tanaka S, Okayama H, Kawaguchi H. Osteoclast differentiation by RANKL requires NF-kappaBmediated downregulation of cyclin-dependent kinase 6 (Cdk6). J Bone Miner Res. 2004; 19:1128-1136.
55. Murgatroyd C, Wu Y, Bockmuhl Y, Spengler D. The Janus face of DNA methylation in aging. Aging (Albany NY). 2010; 2:107-110.
56. Agrawal A, Tay J, Yang GE, Agrawal S, Gupta S. Ageassociated epigenetic modifications in human DNA increase its immunogenicity. Aging (Albany NY). 2010; 2:93-100.
57. Pegoraro G, Misteli T. The central role of chromatin maintenance in aging. Aging (Albany NY). 2009; 1:1017-1022.